SB-4826

N/A

Report date: 2026/03/06 20:02:51
NMEFirst In Class

Base Information

Drug NameSB-4826
Drug Alias NameSB-4826
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSUMO activating enzyme inhibitors
TargetsSUMO activating enzyme
Therapy Area/IndicationsSolid tumoursLymphoma, Non-HodgkinNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncovalent Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San Diego
Inactive CompaniesOncovalent Therapeutics Inc
Active IndicationsSolid tumoursLymphoma, Non-Hodgkin
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A